Ivan Cornella
Company: Covant Therapeutics
Job title: Chief Scientific Officer
Seminars:
Leaving a Permanent Mark: Harnessing Covalent Chemoproteomics to Target Native Proteoforms 9:00 am
Identifying and targeting reactive protein sites in their natural context to modify protein localization and function Condensing reactive warheads against relevant protein sites into a comprehensive library of fragments and lead-like compounds to maximize clinically relevant hits Creating automated workflows integrating mass spectrometry, protein analysis and algorithmic learning to accelerate covalent drug discoveryRead more
day: Conference Day One
Chair’s Opening Remarks 9:20 am
day: Conference Day Two
Chair’s Closing Remarks 4:45 pm
day: Conference Day Two
Panel Discussion: How Can We Build Covalent Chemistries that Drive Selectivity & Open New Unvalidated Target Spaces such as Non-Cysteine Residues 11:15 am
What are some example novel warheads that are being explored to advance covalent modification to new acid residues? How can we effectively target “soft” nucleophiles that are not as reactive as cysteine? Are there unvalidated target spaces that have not yet been drugged which covalency can open up? Such as through nonsmall molecule drugs or…Read more
day: Conference Day Two